InternationalUSRemember you can easily switch between MIP US and MIP International at any time

Get your evidence right


Yang Li and Richeza Herrmann explain how a series of civil cases over trade secrets show the importance of obtaining the right evidence

The infringement of IP is not unique to China, but comes up frequently in discussions about Chinese business. Trade secrets are a particularly sensitive right. In contrast to other kinds of IP, which relate more closely to statutory law, trade secrets are more a creature of jurisprudence. An in-depth knowledge of past court decisions is crucial for the accurate assessment of new cases concerning on this issue. A series of cases examined by Chinese courts in the last 10 years shows what strategies need to be adopted....


Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of one week’s FREE access and become a Managing IP member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain 7 days FREE access when you register now.

Join here

profile

Managing IP

ManagingIP

ManagingIP profile

Re-reading W-L v Actavis patent judgment http://t.co/niQjifQbcg & wondering about likelihood of appeal to @UKSupremeCourt Any views?

May 29 2015 10:40 ·  reply ·  retweet ·  favourite
ManagingIP profile

Wondering how much longer this will take ... #TPP https://t.co/lIqPx5MRLd

May 29 2015 10:27 ·  reply ·  retweet ·  favourite
ManagingIP profile

RT @dietmarlen: Th controversial .sucks registry has extended their sunrise phase and delayed the GA phase. Maybe the FTC report has garner…

May 29 2015 10:20 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


INTA Daily News 2015

Read this year's INTA Daily News - published daily by Managing IP direct from the INTA Annual Meeting in San Diego


June 2015

The fine line between abuse and fair use at the PTAB

Hedge fund manager Kyle Bass has outraged the pharma and biotech industries by seeking to invalidate their patents at the PTAB, with some observers linking his attacks to short-selling of company stocks. Michael Loney reports on a controversy that goes to the heart of the US patent system



Most read articles

Supplements